Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • JB Chemicals Q2 PAT...

    JB Chemicals Q2 PAT jumps 82 pc at Rs 94 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-15T09:32:01+05:30  |  Updated On 15 Nov 2019 9:32 AM IST
    JB Chemicals Q2 PAT jumps 82 pc at Rs 94 crore

    Mumbai: JB Chemicals and Pharmaceuticals Ltd on Tuesday reported 82 per cent jump in its profit after tax during the second quarter at Rs 94 crore from Rs 51 crore in Q2 FY19.


    While sales grew only 5 per cent to Rs 449 crore from Rs 427 crore, other income increased by 116 per cent to Rs 18 crore from Rs 8 crore.


    The increase in other income was mainly on account of higher mark-to-market gain due to an increase in the bond yield during the quarter, the company said in a statement.


    Domestic formulations business at sales of Rs 189 crore registered a growth of 16 per cent. Domestic sales of contrast media products at Rs 15 crore were 12 per cent year-on-year.


    Formulations exports in global business (other than Russia) at Rs 116 crore declined by 8 per cent mainly due to 19 per cent lower sales in the US market. Sales of the company's South African subsidiary at Rs 41 crore were flat.


    Russia-CIS sales at Rs 35 crore registered a growth of 26.13 per cent. Russian subsidiary's sales at Rs 16 crore were 2 per cent higher while exports to Ukraine and other CIS markets at Rs 19 crore were 57 per cent higher year-on-year.


    Read Also: Sun Pharma reports a net profit of Rs 1064 crore in Q2


    Earnings before interest, tax, depreciation and amortisation (EBIDTA) of Rs 100 crore were 22.35 per cent of sales against 17.82 per cent of sales in the corresponding period of the previous year. The higher profitability was a result of cost optimisation.


    JB Chemicals and Pharmaceuticals manufactures and markets a diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients. It has a presence in the United States, Europe, Australia, South Africa other developing countries.


    Read Also: JB Chemicals gets zero USFDA observations for Panoli unit

    amortisationcost optimisationdepreciationdomestic formulations businessEBIDTAjb chemical resultsJB ChemicalsPATPharmaceuticalsprofitQ2 FY19salessept quarterTax
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok